Peptide cheat sheet
A searchable archive of community-reported values, with an open calculator for the values you enter yourself.
Reconstitution calculator
Enter your own vial contents, liquid volume and amount. The result is arithmetic, not an amount or preparation recommendation. Tables assume a 1 mL (100-unit) insulin syringe.
Your own entries only. This draft stays in this browser tab and is not added to the URL.
Units are for a U-100 insulin syringe (100 units = 1 ml).
Free account. Your entered values will be waiting for you on this device.
Save this vial to your trackerFind a reference
58 archive entries. All source links pending verification.
Healing & recovery
Community category label, not an efficacy claim. Source links are pending for every entry.
BPC-157
- Reported vial contents
- 10 mg
- Reported liquid volume
- 2 mL
- Reported amount and frequency
- 250-750 mcg daily
- Reported route
- SubQ
- Reported cycle
- 4-8 wks
- Reported time off
- 2-4 wks
- Markers mentioned
- CBC, CRP, liver
Source: original community compilation. Exact post citation pending; values have not been independently verified.
TB-500
- Reported vial contents
- 10 mg
- Reported liquid volume
- 2 mL
- Reported amount and frequency
- 2-5 mg weekly, split 2x
- Reported route
- SubQ
- Reported cycle
- 4-8 wks
- Reported time off
- 2-4 wks
- Markers mentioned
- CBC, CRP
Source: original community compilation. Exact post citation pending; values have not been independently verified.
BPC-157 + TB-500 (Wolverine)
- Reported vial contents
- 20 mg
- Reported liquid volume
- 2 mL
- Reported amount and frequency
- 250-500 mcg each daily
- Reported route
- SubQ
- Reported cycle
- 4-6 wks
- Reported time off
- 2-4 wks
- Markers mentioned
- CBC, CRP, liver
Source: original community compilation. Exact post citation pending; values have not been independently verified.
GHK-Cu
- Reported vial contents
- 50 mg
- Reported liquid volume
- 2 mL
- Reported amount and frequency
- 1-2.5 mg, 2-3x weekly
- Reported route
- SubQ / topical
- Reported cycle
- 4-8 wks
- Reported time off
- 2-4 wks
- Markers mentioned
- Serum copper, liver
Source: original community compilation. Exact post citation pending; values have not been independently verified.
KPV
- Reported vial contents
- 10 mg
- Reported liquid volume
- 2 mL
- Reported amount and frequency
- 250 mcg - 1 mg daily
- Reported route
- SubQ
- Reported cycle
- 4-8 wks
- Reported time off
- 2-4 wks
- Markers mentioned
- CRP, CBC
Source: original community compilation. Exact post citation pending; values have not been independently verified.
LL-37
- Reported vial contents
- 5 mg
- Reported liquid volume
- 3 mL
- Reported amount and frequency
- 50-400 mcg daily
- Reported route
- SubQ
- Reported cycle
- 2-6 wks
- Reported time off
- 2-4 wks
- Markers mentioned
- CBC, CRP, liver
Source: original community compilation. Exact post citation pending; values have not been independently verified.
Thymosin Alpha-1
- Reported vial contents
- 10 mg
- Reported liquid volume
- 2 mL
- Reported amount and frequency
- 1.6 mg twice weekly
- Reported route
- SubQ
- Reported cycle
- 4-12 wks
- Reported time off
- 4 wks
- Markers mentioned
- CBC diff, CD4/CD8, CRP
Source: original community compilation. Exact post citation pending; values have not been independently verified.
GLOW blend
- Reported vial contents
- 70 mg
- Reported liquid volume
- 3 mL
- Reported amount and frequency
- ~1.67 mg daily (GHK anchor)
- Reported route
- SubQ
- Reported cycle
- 4-6 wks
- Reported time off
- 2-4 wks
- Markers mentioned
- Serum copper, CBC
Source: original community compilation. Exact post citation pending; values have not been independently verified.
KLOW blend
- Reported vial contents
- 80 mg
- Reported liquid volume
- 3 mL
- Reported amount and frequency
- ~1.67 mg daily (GHK anchor)
- Reported route
- SubQ
- Reported cycle
- 4-6 wks
- Reported time off
- 2-4 wks
- Markers mentioned
- CBC, CRP, serum copper
Source: original community compilation. Exact post citation pending; values have not been independently verified.
Fat loss & metabolic
Community category label, not an efficacy claim. Source links are pending for every entry.
Semaglutide
- Reported vial contents
- 10 mg
- Reported liquid volume
- 2 mL
- Reported amount and frequency
- 0.25-2.4 mg weekly (reported range)
- Reported route
- SubQ
- Reported cycle
- 12-16+ wks
- Reported time off
- None fixed
- Markers mentioned
- Glucose, HbA1c, lipids, amylase/lipase
Source: original community compilation. Exact post citation pending; values have not been independently verified.
Tirzepatide
- Reported vial contents
- 10 mg
- Reported liquid volume
- 2 mL
- Reported amount and frequency
- 2.5-15 mg weekly (reported range)
- Reported route
- SubQ
- Reported cycle
- 12-16+ wks
- Reported time off
- None fixed
- Markers mentioned
- Same as semaglutide
Source: original community compilation. Exact post citation pending; values have not been independently verified.
Retatrutide
- Reported vial contents
- 10 mg
- Reported liquid volume
- 2 mL
- Reported amount and frequency
- 0.5-12 mg weekly (reported range)
- Reported route
- SubQ
- Reported cycle
- 24-48+ wks
- Reported time off
- None standard
- Markers mentioned
- Glucose, HbA1c, lipids; dysesthesia mentioned in compilation
Source: original community compilation. Exact post citation pending; values have not been independently verified.
Cagrilintide
- Reported vial contents
- 5 mg
- Reported liquid volume
- 2 mL
- Reported amount and frequency
- 0.6-4.5 mg weekly
- Reported route
- SubQ
- Reported cycle
- 12-24 wks
- Reported time off
- None standard
- Markers mentioned
- Same as GLP-1s
Source: original community compilation. Exact post citation pending; values have not been independently verified.
Cagrilintide + Semaglutide
- Reported vial contents
- 10 mg blend
- Reported liquid volume
- Per blend
- Reported amount and frequency
- 2.4 mg each weekly
- Reported route
- SubQ
- Reported cycle
- 8-16+ wks
- Reported time off
- 4-6 wks
- Markers mentioned
- Same as GLP-1s
Source: original community compilation. Exact post citation pending; values have not been independently verified.
Tesamorelin
- Reported vial contents
- 10 mg
- Reported liquid volume
- 2 mL
- Reported amount and frequency
- 1-2 mg daily
- Reported route
- SubQ
- Reported cycle
- 12+ wks
- Reported time off
- Goal-dependent
- Markers mentioned
- IGF-1, glucose, hs-CRP
Source: original community compilation. Exact post citation pending; values have not been independently verified.
AOD-9604
- Reported vial contents
- 5 mg
- Reported liquid volume
- 3 mL
- Reported amount and frequency
- 250-500 mcg daily, fasted
- Reported route
- SubQ
- Reported cycle
- 4-12 wks
- Reported time off
- 2-4 wks
- Markers mentioned
- Basic metabolic
Source: original community compilation. Exact post citation pending; values have not been independently verified.
HGH Frag 176-191
- Reported vial contents
- 5 mg
- Reported liquid volume
- 2 mL
- Reported amount and frequency
- 250-500 mcg daily, split 2x
- Reported route
- SubQ
- Reported cycle
- 4-12 wks
- Reported time off
- 2-4 wks
- Markers mentioned
- Basic metabolic
Source: original community compilation. Exact post citation pending; values have not been independently verified.
MOTS-c
- Reported vial contents
- 10 mg
- Reported liquid volume
- 3 mL isotonic
- Reported amount and frequency
- 5-10 mg weekly, split
- Reported route
- SubQ
- Reported cycle
- 4-8 wks
- Reported time off
- 2-4 wks
- Markers mentioned
- HbA1c, insulin, lipids
Source: original community compilation. Exact post citation pending; values have not been independently verified.
5-Amino-1MQ
- Reported vial contents
- 10 mg
- Reported liquid volume
- 2 mL
- Reported amount and frequency
- Oral 50-150 mg / SubQ 0.5-3.3 mg daily
- Reported route
- Oral / SubQ
- Reported cycle
- 4-8 wks
- Reported time off
- 2-4 wks
- Markers mentioned
- Glucose, insulin, liver
Source: original community compilation. Exact post citation pending; values have not been independently verified.
SLU-PP-332
- Reported vial contents
- 5 mg
- Reported liquid volume
- 2 mL
- Reported amount and frequency
- 250 mcg daily
- Reported route
- SubQ
- Reported cycle
- 4-8 wks
- Reported time off
- 2-4 wks
- Markers mentioned
- Basic metabolic
Source: original community compilation. Exact post citation pending; values have not been independently verified.
Growth hormone & recovery
Community category label, not an efficacy claim. Source links are pending for every entry.
CJC-1295 + Ipamorelin
- Reported vial contents
- 10 mg blend
- Reported liquid volume
- 2 mL
- Reported amount and frequency
- 100-300 mcg each, daily (PM, fasted)
- Reported route
- SubQ
- Reported cycle
- 8-12 wks
- Reported time off
- 3-4 wks
- Markers mentioned
- IGF-1, glucose
Source: original community compilation. Exact post citation pending; values have not been independently verified.
CJC-1295 DAC
- Reported vial contents
- 5 mg
- Reported liquid volume
- 2 mL
- Reported amount and frequency
- 300-1000 mcg, 1-2x weekly
- Reported route
- SubQ
- Reported cycle
- 8-12 wks
- Reported time off
- 3-4 wks
- Markers mentioned
- IGF-1, glucose
Source: original community compilation. Exact post citation pending; values have not been independently verified.
Ipamorelin
- Reported vial contents
- 10 mg
- Reported liquid volume
- 2 mL
- Reported amount and frequency
- 100-300 mcg daily
- Reported route
- SubQ
- Reported cycle
- 8-12 wks
- Reported time off
- 3-4 wks
- Markers mentioned
- IGF-1, glucose
Source: original community compilation. Exact post citation pending; values have not been independently verified.
Sermorelin
- Reported vial contents
- 5 mg
- Reported liquid volume
- 2 mL
- Reported amount and frequency
- 200-300 mcg nightly
- Reported route
- SubQ
- Reported cycle
- 8-16 wks
- Reported time off
- 3-4 wks
- Markers mentioned
- IGF-1, glucose
Source: original community compilation. Exact post citation pending; values have not been independently verified.
GHRP-2
- Reported vial contents
- 5 mg
- Reported liquid volume
- 2 mL
- Reported amount and frequency
- 100-300 mcg 1-3x daily
- Reported route
- SubQ
- Reported cycle
- 6-12 wks
- Reported time off
- 3-4 wks
- Markers mentioned
- IGF-1, prolactin, cortisol
Source: original community compilation. Exact post citation pending; values have not been independently verified.
GHRP-6
- Reported vial contents
- 5 mg
- Reported liquid volume
- 2 mL
- Reported amount and frequency
- 100-300 mcg 1-3x daily
- Reported route
- SubQ
- Reported cycle
- 6-12 wks
- Reported time off
- 3-4 wks
- Markers mentioned
- IGF-1, prolactin, cortisol
Source: original community compilation. Exact post citation pending; values have not been independently verified.
IGF-1 LR3
- Reported vial contents
- 1 mg
- Reported liquid volume
- 1 mL acetic acid
- Reported amount and frequency
- 20-50 mcg daily
- Reported route
- SubQ
- Reported cycle
- 4-6 wks
- Reported time off
- 4 wks
- Markers mentioned
- IGF-1, glucose, kidney
Source: original community compilation. Exact post citation pending; values have not been independently verified.
PEG-MGF
- Reported vial contents
- 2 mg
- Reported liquid volume
- 3 mL
- Reported amount and frequency
- 200-500 mcg daily
- Reported route
- SubQ
- Reported cycle
- 8 wks
- Reported time off
- 4 wks
- Markers mentioned
- IGF-1, CBC
Source: original community compilation. Exact post citation pending; values have not been independently verified.
Follistatin-344
- Reported vial contents
- 1 mg
- Reported liquid volume
- 2 mL
- Reported amount and frequency
- 50-100 mcg daily (local placement reported)
- Reported route
- SubQ
- Reported cycle
- 10-30 days
- Reported time off
- 4-6 wks
- Markers mentioned
- IGF-1, CBC
Source: original community compilation. Exact post citation pending; values have not been independently verified.
Cognitive & mood
Community category label, not an efficacy claim. Source links are pending for every entry.
Semax
- Reported vial contents
- 10 mg
- Reported liquid volume
- 2 mL
- Reported amount and frequency
- Inj 200-600 mcg / IN 50-100 mcg per nostril 1-3x
- Reported route
- Intranasal (reported)
- Reported cycle
- 2-4 wks
- Reported time off
- 1-2 wks
- Markers mentioned
- Not recorded
Source: original community compilation. Exact post citation pending; values have not been independently verified.
Selank
- Reported vial contents
- 5 mg
- Reported liquid volume
- 2 mL
- Reported amount and frequency
- Inj 250-500 mcg / IN 125-250 mcg per nostril 1-3x
- Reported route
- Intranasal (reported)
- Reported cycle
- 2-4 wks
- Reported time off
- 1-2 wks
- Markers mentioned
- Not recorded
Source: original community compilation. Exact post citation pending; values have not been independently verified.
Adamax
- Reported vial contents
- 10 mg
- Reported liquid volume
- 3 mL
- Reported amount and frequency
- 300-1000 mcg daily (reported range)
- Reported route
- SubQ
- Reported cycle
- 8-12 wks
- Reported time off
- Equal break
- Markers mentioned
- Not recorded
Source: original community compilation. Exact post citation pending; values have not been independently verified.
Oxytocin
- Reported vial contents
- 10 mg
- Reported liquid volume
- 3 mL
- Reported amount and frequency
- IN 8 IU per nostril / inj 1-10 IU
- Reported route
- Both
- Reported cycle
- As needed
- Reported time off
- Not recorded
- Markers mentioned
- Not recorded
Source: original community compilation. Exact post citation pending; values have not been independently verified.
Dihexa
- Reported vial contents
- n/a
- Reported liquid volume
- n/a
- Reported amount and frequency
- Oral 10-30 mg / topical 3-5 mg daily
- Reported route
- Oral / topical
- Reported cycle
- 2-6 wks
- Reported time off
- 2-4 wks
- Markers mentioned
- Not recorded
Source: original community compilation. Exact post citation pending; values have not been independently verified.
Kisspeptin-10
- Reported vial contents
- 10 mg
- Reported liquid volume
- 2 mL
- Reported amount and frequency
- 100-200 mcg daily
- Reported route
- SubQ, fasted
- Reported cycle
- 4-8 wks
- Reported time off
- 2-4 wks
- Markers mentioned
- Not recorded
Source: original community compilation. Exact post citation pending; values have not been independently verified.
Cerebrolysin
- Reported vial contents
- 60 mg
- Reported liquid volume
- 3 mL
- Reported amount and frequency
- 20-32 mg daily (reported range)
- Reported route
- SubQ
- Reported cycle
- 8-12 wks
- Reported time off
- Between courses
- Markers mentioned
- Not recorded
Source: original community compilation. Exact post citation pending; values have not been independently verified.
P21
- Reported vial contents
- 10 mg
- Reported liquid volume
- 2 mL
- Reported amount and frequency
- 100-300 mcg daily, AM
- Reported route
- SubQ
- Reported cycle
- 5-14 days per course
- Reported time off
- 2-3 months between
- Markers mentioned
- Not recorded
Source: original community compilation. Exact post citation pending; values have not been independently verified.
PE-22-28
- Reported vial contents
- 10 mg
- Reported liquid volume
- 3 mL
- Reported amount and frequency
- 50-200 mcg daily
- Reported route
- SubQ
- Reported cycle
- 12-16 wks
- Reported time off
- Equal break
- Markers mentioned
- Not recorded
Source: original community compilation. Exact post citation pending; values have not been independently verified.
Immune & longevity
Community category label, not an efficacy claim. Source links are pending for every entry.
Thymosin Alpha-1
- Reported vial contents
- 10 mg
- Reported liquid volume
- 2 mL
- Reported amount and frequency
- 1.6 mg twice weekly
- Reported route
- SubQ
- Reported cycle
- 4-12 wks
- Reported time off
- 4 wks
- Markers mentioned
- CBC diff, CD4/CD8, CRP
Source: original community compilation. Exact post citation pending; values have not been independently verified.
Epitalon
- Reported vial contents
- 10 mg
- Reported liquid volume
- 2 mL
- Reported amount and frequency
- 5-10 mg daily for 10 days
- Reported route
- SubQ
- Reported cycle
- 1-2x per year
- Reported time off
- 3-6 months
- Markers mentioned
- Telomere testing mentioned
Source: original community compilation. Exact post citation pending; values have not been independently verified.
NAD+
- Reported vial contents
- 500 mg
- Reported liquid volume
- 5 mL
- Reported amount and frequency
- SubQ 25-100 mg / oral 250-500 mg daily
- Reported route
- SubQ / oral
- Reported cycle
- 4-12 wks
- Reported time off
- 2-4 wks
- Markers mentioned
- CBC, CMP
Source: original community compilation. Exact post citation pending; values have not been independently verified.
MOTS-c
- Reported vial contents
- 10 mg
- Reported liquid volume
- 3 mL isotonic
- Reported amount and frequency
- 5-10 mg weekly, split
- Reported route
- SubQ
- Reported cycle
- 4-8 wks
- Reported time off
- 2-4 wks
- Markers mentioned
- HbA1c, insulin
Source: original community compilation. Exact post citation pending; values have not been independently verified.
SS-31 (Elamipretide)
- Reported vial contents
- 10 mg
- Reported liquid volume
- 1 mL isotonic
- Reported amount and frequency
- 5-10 mg daily
- Reported route
- SubQ
- Reported cycle
- 4-8 wks
- Reported time off
- 2-4 wks
- Markers mentioned
- Basic metabolic
Source: original community compilation. Exact post citation pending; values have not been independently verified.
Pinealon
- Reported vial contents
- 10 mg
- Reported liquid volume
- 3 mL
- Reported amount and frequency
- SubQ 1-2 mg / oral 0.2 mg twice daily
- Reported route
- SubQ / oral
- Reported cycle
- 10-20 days per course
- Reported time off
- 3-6 months
- Markers mentioned
- Not recorded
Source: original community compilation. Exact post citation pending; values have not been independently verified.
Vesugen
- Reported vial contents
- 20 mg
- Reported liquid volume
- 3 mL
- Reported amount and frequency
- 500 mcg - 2 mg daily (reported range)
- Reported route
- SubQ
- Reported cycle
- 8-12 wks
- Reported time off
- Between courses
- Markers mentioned
- Not recorded
Source: original community compilation. Exact post citation pending; values have not been independently verified.
Sexual & cosmetic
Community category label, not an efficacy claim. Source links are pending for every entry.
PT-141
- Reported vial contents
- 10 mg
- Reported liquid volume
- 2 mL
- Reported amount and frequency
- 1-2 mg
- Reported route
- Inj / intranasal
- Reported cycle
- As needed
- Reported time off
- Not recorded
- Markers mentioned
- BP monitoring
Source: original community compilation. Exact post citation pending; values have not been independently verified.
Melanotan II
- Reported vial contents
- 10 mg
- Reported liquid volume
- 2 mL
- Reported amount and frequency
- Reported phases: 250 mcg; 500 mcg daily for 1-4 wks; 500 mcg weekly-biweekly
- Reported route
- SubQ
- Reported cycle
- 4-8 wks
- Reported time off
- Not recorded
- Markers mentioned
- BP + mole exam
Source: original community compilation. Exact post citation pending; values have not been independently verified.
GHK-Cu
- Reported vial contents
- 50 mg
- Reported liquid volume
- 4 mL
- Reported amount and frequency
- Inj 1-2.5 mg, 2-3x weekly
- Reported route
- Both
- Reported cycle
- 4-8 wks
- Reported time off
- Not recorded
- Markers mentioned
- Serum copper
Source: original community compilation. Exact post citation pending; values have not been independently verified.
Oxytocin
- Reported vial contents
- 10 mg
- Reported liquid volume
- 3 mL
- Reported amount and frequency
- IN 8 IU per nostril / inj 1-10 IU
- Reported route
- Both
- Reported cycle
- As needed
- Reported time off
- Not recorded
- Markers mentioned
- Not recorded
Source: original community compilation. Exact post citation pending; values have not been independently verified.
SNAP-8
- Reported vial contents
- 10 mg
- Reported liquid volume
- 3 mL
- Reported amount and frequency
- 330-1000 mcg daily (reported range)
- Reported route
- SubQ / topical
- Reported cycle
- 8-12 wks
- Reported time off
- Not recorded
- Markers mentioned
- Not recorded
Source: original community compilation. Exact post citation pending; values have not been independently verified.
Bioregulators (Khavinson short peptides)
Community category label, not an efficacy claim. Source links are pending for every entry.
Cartalax (cartilage/connective)
- Reported vial contents
- 20 mg
- Reported liquid volume
- 3 mL
- Reported amount and frequency
- 2-5 mg daily (reported range)
- Reported route
- SubQ
- Reported cycle
- 8-12 wks
- Reported time off
- Not recorded
- Markers mentioned
- Not recorded
Source: original community compilation. Exact post citation pending; values have not been independently verified.
Cortagen (neural/cognitive)
- Reported vial contents
- 20 mg
- Reported liquid volume
- 3 mL
- Reported amount and frequency
- 1-2 mg daily
- Reported route
- SubQ
- Reported cycle
- 4-8 wks
- Reported time off
- Not recorded
- Markers mentioned
- Not recorded
Source: original community compilation. Exact post citation pending; values have not been independently verified.
Ovagen (GI/hepatic)
- Reported vial contents
- 20 mg
- Reported liquid volume
- 2 mL
- Reported amount and frequency
- 10-150 mcg daily
- Reported route
- SubQ
- Reported cycle
- 16 wks
- Reported time off
- Not recorded
- Markers mentioned
- Liver panel
Source: original community compilation. Exact post citation pending; values have not been independently verified.
Prostamax (prostate)
- Reported vial contents
- 20 mg
- Reported liquid volume
- 2 mL
- Reported amount and frequency
- 500 mcg - 1 mg daily
- Reported route
- IM
- Reported cycle
- 8-12 wks
- Reported time off
- Not recorded
- Markers mentioned
- Not recorded
Source: original community compilation. Exact post citation pending; values have not been independently verified.
Testagen (endocrine/gonadal)
- Reported vial contents
- 20 mg
- Reported liquid volume
- 3 mL
- Reported amount and frequency
- 100-300 mcg daily
- Reported route
- SubQ
- Reported cycle
- 8-12 wks
- Reported time off
- Not recorded
- Markers mentioned
- Hormone panel
Source: original community compilation. Exact post citation pending; values have not been independently verified.
Advanced & research-only
Community category label, not an efficacy claim. Source links are pending for every entry.
Ara-290 (cibinetide)
- Reported vial contents
- 16 mg
- Reported liquid volume
- 5 mL
- Reported amount and frequency
- 4 mg daily
- Reported route
- SubQ
- Reported cycle
- 28 days - 12 wks
- Reported time off
- Not recorded
- Markers mentioned
- Not recorded
Source: original community compilation. Exact post citation pending; values have not been independently verified.
VIP
- Reported vial contents
- 10 mg
- Reported liquid volume
- 2 mL (SubQ)
- Reported amount and frequency
- IN 50-100 mcg / SubQ 50-200 mcg, AM
- Reported route
- IN / SubQ
- Reported cycle
- 4 wks - 18 months
- Reported time off
- Not recorded
- Markers mentioned
- Not recorded
Source: original community compilation. Exact post citation pending; values have not been independently verified.
DSIP
- Reported vial contents
- 5 mg
- Reported liquid volume
- 3 mL
- Reported amount and frequency
- 100-300 mcg pre-bed
- Reported route
- SubQ
- Reported cycle
- 8-12 wks, 5 on / 2 off
- Reported time off
- Not recorded
- Markers mentioned
- Not recorded
Source: original community compilation. Exact post citation pending; values have not been independently verified.
Keep an existing protocol in one place.
Record compound names, amounts and schedules from your own plan. Peptarget does not choose them for you.
Create a free account